Tag Archives: NASDAQ:CLSN

Quick News Overview of Healthcare Sector: Allscripts Healthcare (NASDAQ:MDRX), Dendreon (NASDAQ:DNDN) – MDRX, DNDN, CLSN, AFFY, DNDN, DCTH

Posted on May 10, 2013 by Thomas Vedder

Healthcare sector finished negatively on Thursday’s trading session and sector moved down -0.12%. If we consider key percentage decliners of this sector so Affymax, Inc (NASDAQ:AFFY) was major percentage gainer while key percentage decliners were Dendreon Corporation (NASDAQ:DNDN) and Delcath …

Posted in Healthcare, Latest Headlines | Tagged AFFY, Affymax, Allscripts Healthcare, Celsion, CLSN, DCTH, Delcath, Dendreon, DNDN, MDRX, NASDAQ:AFFY, NASDAQ:CLSN, NASDAQ:DCTH, NASDAQ:DNDN, NASDAQ:MDRX | Comments Off

Coventry Health Care (NYSE:CVH) Q4 Profit Outshines Wall Street Forecasts But Revenue Misses Estimates – CVH, AET, UNH, DNDN, CLDX, CLSN, PFE, BSX, ELN

Posted on February 6, 2013 by Geoff Noir

The Bethesda, Maryland-based Coventry Health Care, Inc (NYSE:CVH), which is being purchased by health insurer Aetna Inc (NYSE:AET), announced a profit for fiscal Q4 that hiked from previous year, showing strong operating margins amid lower costs and revenue expansion.

Managed …

Posted in Healthcare, Latest Headlines | Tagged AET, Aetna, Boston Scientific, BSX, Celldex Therapeutics, Celsion, CLDX, CLSN, Coventry Health Care, CVH, Dendreon, DNDN, Elan Corporation, ELN, NASDAQ:CLDX, NASDAQ:CLSN, NASDAQ:DNDN, NYSE:AET, NYSE:BSX, NYSE:CVH, NYSE:ELN, NYSE:PFE, NYSE:UNH, PFE, Pfizer, UNH, UnitedHealth | Comments Off

Merck (NYSE:MRK) Shatters Profit Guidance for Fiscal Year 2013; Fiscal Q4 Net Income Tumbles – MRK, GSK, NVS, BMY, GILD, JNJ, HLF, TEVA, CLSN

Posted on February 1, 2013 by Thomas Vedder

The Whitehouse Station, New Jersey-based Merck & Co, Inc’s (NYSE:MRK) current year profit forecasts tumbles as generic rivalry to its best selling medicine Singular will damage results.

The drug giant announced that earnings will be in the range of $3.60 …

Posted in Healthcare, Latest Headlines | Tagged BMY, Bristol-Myers Squibb, Celsion, CLSN, GILD, Gilead Sciences, GlaxoSmithKline, GSK, Herbalife, HLF, JNJ, Johnson & Johnson, Merck, MRK, NASDAQ:CLSN, NASDAQ:GILD, Novartis, NVS, NYSE:BMY, NYSE:GSK, NYSE:HLF, NYSE:JNJ, NYSE:MRK, NYSE:NVS, NYSE:TEVA, TEVA, Teva Pharmaceutical Industries | Comments Off

Aetna (NYSE:AET) Net Plunges 49% in Fiscal Q4 on Reimbursement Settlement – AET, BSX, ABIO, KERX, CLSN, GNBT, ABBV, CI, UNH

Posted on January 31, 2013 by Geoff Noir

Aetna Inc (NYSE:AET) reported that fiscal Q4 profit moved down 49% after the third-biggest United States health insurer decided to pay around $120 million to fix a court case regarding its payments to doctors.

The Hartford, Connecticut-based Aetna reported in …

Posted in Healthcare, Latest Headlines | Tagged ABBV, AbbVie, ABIO, AET, Aetna, ARCA biopharma, Boston Scientific, BSX, Celsion, CI, Cigna, CLSN, Generex Biotechnology, GNBT, KERX, Keryx Biopharmaceuticals, NASDAQ:ABIO, NASDAQ:CLSN, NASDAQ:KERX, NYSE:ABBV, NYSE:AET, NYSE:BSX, NYSE:CI, NYSE:UNH, OTC:GNBT, UNH, UnitedHealth | Comments Off

Biogen Idec (NASDAQ:BIIB) Post 2.7% Drop in Fiscal Q4 on Higher Outlays – BIIB, CELG, GILD, CLSN, KERX, PFE, BSX, BMY, HLF

Posted on January 28, 2013 by Geoff Noir

Biogen Idec Inc (NASDAQ:BIIB) reported fiscal Q4 earnings moved down 2.7% as the company’s attempts to increase its output pipeline masked its revenue expansion.

The biotechnology company also estimates fiscal year 2013 adjusted earnings in the range of $7.15 to …

Posted in Healthcare, Latest Headlines | Tagged BIIB, Biogen Idec, BMY, Boston Scientific, Bristol-Myers Squibb, BSX, CELG, Celgene, Celsion, CLSN, GILD, Gilead Sciences, Herbalife, HLF, KERX, Keryx Biopharmaceuticals, NASDAQ:BIIB, NASDAQ:CELG, NASDAQ:CLSN, NASDAQ:GILD, NASDAQ:KERX, NYSE:BMY, NYSE:BSX, NYSE:HLF, NYSE:PFE, PFE, Pfizer | Comments Off

Johnson & Johnson (NYSE:JNJ) Reports Fiscal Fourth Quarter Results – JNJ, COV, NVS, BSX, CLSN, PATH, BSX, PFE, MRK

Posted on January 22, 2013 by Thomas Vedder

Johnson & Johnson (NYSE:JNJ) on Tuesday reported sales of $17.6 billion for the fiscal Q4 of 2012, an boost of 8.0% as evaluated against the fiscal Q4 of 2011.

The drug giant announced that operational results moved up 9.3% and …

Posted in Healthcare, Latest Headlines | Tagged Boston Scientific, BSX, Celsion, CLSN, COV, Covidien, JNJ, Johnson & Johnson, Merck, MRK, NASDAQ:CLSN, NASDAQ:PATH, Novartis, NuPathe, NVS, NYSE:BSX, NYSE:COV, NYSE:JNJ, NYSE:MRK, NYSE:NVS, NYSE:PFE, PATH, PFE, Pfizer | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.